MedTrace Logo

Effect of the TEGO Connector in Preventing Tunneled Cuffed Hemodialysis Catheters From Dysfunction and/or Bacteremia

NCT01689753 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2012-09-26

No results posted yet for this study

Summary

The aim of the trial was to assess whether use of the TEGO connector was able to reduce the incidence of a composite endpoint of TCC-related dysfunction (TCC-D)or TCC-related bacteremia (TCC-B) in chronic hemodialysis (HD) patients carrying the TEGO® connector vs controls receiving trisodium citrate 46.7%.

Conditions

  • Other Complication of Vascular Dialysis Catheter

Interventions

DEVICE

TEGO connector®

DRUG

Trisodium citrate

Sponsors & Collaborators

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Joëlle Nortier, MD, PhD · Nephrology Dept, Erasme Hospital. Université Libre de Bruxelles, Brussel

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-04-30
Completion
2011-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01689753 on ClinicalTrials.gov